Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Viridian Therapeutics and keeping the price target at $46.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight Viridian Therapeutics’ promising prospects. The company has successfully submitted a Biologics License Application (BLA) for veligrotug, a treatment for Thyroid Eye Disease (TED), which is supported by positive results from their THRIVE program. This submission, along with a request for Priority Review, positions the company for a potential mid-2026 commercial launch, pending FDA approval. The clinical differentiation of veligrotug, including faster efficacy onset and significant benefits for chronic TED patients, suggests a strong market uptake.
Additionally, Viridian plans to present pivotal trial results for another promising therapy, VRDN-003, in 2026, which shares similar properties with veligrotug. The anticipated preference for VRDN-003’s self-administered format could expand its market reach. Furthermore, Viridian’s financial stability, bolstered by a recent royalty financing agreement, is expected to support the commercial launches of these therapies. These factors collectively suggest that Viridian’s innovative treatments could capture a significant portion of the TED market, justifying the Buy rating.
In another report released on October 27, Wedbush also maintained a Buy rating on the stock with a $42.00 price target.